159 related articles for article (PubMed ID: 21317222)
1. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation.
Hui EP; Ma BBY; King AD; Mo F; Chan SL; Kam MKM; Loong HH; Ahuja AT; Zee BCY; Chan ATC
Ann Oncol; 2011 Jun; 22(6):1280-1287. PubMed ID: 21317222
[TBL] [Abstract][Full Text] [Related]
2. Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?
Soria JC; Deutsch E
Ann Oncol; 2011 Jun; 22(6):1247-1249. PubMed ID: 21382869
[No Abstract] [Full Text] [Related]
3. Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
Choong NW; Kozloff M; Taber D; Hu HS; Wade J; Ivy P; Karrison TG; Dekker A; Vokes EE; Cohen EE
Invest New Drugs; 2010 Oct; 28(5):677-83. PubMed ID: 19649772
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases.
Novello S; Camps C; Grossi F; Mazieres J; Abrey L; Vernejoux JM; Thall A; Patyna S; Usari T; Wang Z; Chao RC; Scagliotti G
J Thorac Oncol; 2011 Jul; 6(7):1260-6. PubMed ID: 21610524
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic blockade and radiotherapy in hepatocellular carcinoma.
Chi KH; Liao CS; Chang CC; Ko HL; Tsang YW; Yang KC; Mehta MP
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):188-93. PubMed ID: 20133077
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Burstein HJ; Elias AD; Rugo HS; Cobleigh MA; Wolff AC; Eisenberg PD; Lehman M; Adams BJ; Bello CL; DePrimo SE; Baum CM; Miller KD
J Clin Oncol; 2008 Apr; 26(11):1810-6. PubMed ID: 18347007
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
12. Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03).
Jakob J; Simeonova A; Kasper B; Ronellenfitsch U; Rauch G; Wenz F; Hohenberger P
Radiat Oncol; 2016 Jun; 11():77. PubMed ID: 27255678
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.
Mackay HJ; Tinker A; Winquist E; Thomas G; Swenerton K; Oza A; Sederias J; Ivy P; Eisenhauer EA
Gynecol Oncol; 2010 Feb; 116(2):163-7. PubMed ID: 19740535
[TBL] [Abstract][Full Text] [Related]
14. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Schneider BJ; Gadgeel SM; Ramnath N; Wozniak AJ; Dy GK; Daignault S; Kalemkerian GP
J Thorac Oncol; 2011 Jun; 6(6):1117-20. PubMed ID: 21512407
[TBL] [Abstract][Full Text] [Related]
18. Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.
Chen Q; Tang L; Liu N; Han F; Guo L; Guo S; Wang J; Liu H; Ye Y; Zhang L; Liu L; Wang P; Li Y; He Q; Yang X; Tang Q; Li Y; Liang Y; Sun X; Xie C; Mo Y; Guo Y; Sun R; Mo H; Cao K; Guo X; Zeng M; Mai H; Ma J
Cancer Commun (Lond); 2018 Nov; 38(1):66. PubMed ID: 30382933
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.
Machiels JP; Henry S; Zanetta S; Kaminsky MC; Michoux N; Rommel D; Schmitz S; Bompas E; Dillies AF; Faivre S; Moxhon A; Duprez T; Guigay J
J Clin Oncol; 2010 Jan; 28(1):21-8. PubMed ID: 19917865
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
Ansari J; Fatima A; Fernando K; Collins S; James ND; Porfiri E
Oncol Rep; 2010 Aug; 24(2):507-10. PubMed ID: 20596640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]